Industry Research Reports
Home > Reports > Medical Devices & Consumables > Global Infectious Diseases Molecular Diagnostics Kit Market Outlook, In‑Depth Analysis & Forecast to 2031
Global Infectious Diseases Molecular Diagnostics Kit Market Outlook, In‑Depth Analysis & Forecast to 2031
Industry: Medical Devices & Consumables
Published Date: 2025-11-02
Pages: 142 Pages
Report ld: 5345104
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Infectious Diseases Molecular Diagnostics Kit Market Size(US$)
CAGR 2025-2031
7.5%
Market Size,2031
USD 32,840
Million
Market Snapshot
Market Size in 2025 (Value)
US$ 21,280 million
Market Forecast in 2031(Value)
US$ 32,840 million
CAGR
7.5%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Infectious Diseases Molecular Diagnostics Kit market is projected to grow from US$ 19930 million in 2024 to US$ 32840 million by 2031, at a CAGR of 7.5% (2025-2031), driven by critical product segments and diverse end‑use applications.
The implications of current trends in molecular infectious diseases are moving towards high-throughput, simple, array-type technologies that will provide a wealth of data regarding types of organisms present in a sample and the virulence factors/resistance determinants that influence the severity of disease. As a result of these developments, infectious diseases will be more accurately and effectively treated.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Includes:
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Infectious Diseases Molecular Diagnostics Kit market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
MARKET SEGMENTATION
By Company
- Roche
- Qiagen
- Illumina
- Abbott
- Hologic
- BioMerieux
- Danaher (Cepheid)
- Myriad Genetics
- DAAN Gene
- Agilent
- Genomic Health
- BD
- Foundation Medicine
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Polymerase Chain Reaction PCR
- Molecular Hybridization
- Biochip
- Others
Segment by Application
- Hospital
- Third-party Testing Agency
- Others
CHAPTER OUTLINE
Chapter 1: Defines the Infectious Diseases Molecular Diagnostics Kit study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; top-tier players 2024 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Introduction to Infectious Diseases Molecular Diagnostics Kit: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Infectious Diseases Molecular Diagnostics Kit Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Polymerase Chain Reaction PCR
1.2.3 Molecular Hybridization
1.2.4 Biochip
1.2.5 Others
1.3 Market Segmentation by Application
1.3.1 Global Infectious Diseases Molecular Diagnostics Kit Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Third-party Testing Agency
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Infectious Diseases Molecular Diagnostics Kit Revenue Estimates and Forecasts 2020-2031
2.2 Global Infectious Diseases Molecular Diagnostics Kit Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Infectious Diseases Molecular Diagnostics Kit Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Infectious Diseases Molecular Diagnostics Kit Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Polymerase Chain Reaction PCR Market Size by Players
3.3.2 Molecular Hybridization Market Size by Players
3.3.3 Biochip Market Size by Players
3.3.4 Others Market Size by Players
3.4 Global Infectious Diseases Molecular Diagnostics Kit Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Infectious Diseases Molecular Diagnostics Kit Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Infectious Diseases Molecular Diagnostics Kit Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Infectious Diseases Molecular Diagnostics Kit Market Size by Type (2020-2031)
6.4 North America Infectious Diseases Molecular Diagnostics Kit Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Infectious Diseases Molecular Diagnostics Kit Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Infectious Diseases Molecular Diagnostics Kit Market Size by Type (2020-2031)
7.4 Europe Infectious Diseases Molecular Diagnostics Kit Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Infectious Diseases Molecular Diagnostics Kit Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Infectious Diseases Molecular Diagnostics Kit Market Size by Type (2020-2031)
8.4 Asia-Pacific Infectious Diseases Molecular Diagnostics Kit Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Infectious Diseases Molecular Diagnostics Kit Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Infectious Diseases Molecular Diagnostics Kit Market Size by Type (2020-2031)
9.4 Central and South America Infectious Diseases Molecular Diagnostics Kit Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Infectious Diseases Molecular Diagnostics Kit Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Infectious Diseases Molecular Diagnostics Kit Market Size by Type (2020-2031)
10.4 Middle East and Africa Infectious Diseases Molecular Diagnostics Kit Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Infectious Diseases Molecular Diagnostics Kit Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Roche
11.1.1 Roche Corporation Information
11.1.2 Roche Business Overview
11.1.3 Roche Infectious Diseases Molecular Diagnostics Kit Product Features and Attributes
11.1.4 Roche Infectious Diseases Molecular Diagnostics Kit Revenue and Gross Margin (2020-2025)
11.1.5 Roche Infectious Diseases Molecular Diagnostics Kit Revenue by Product in 2024
11.1.6 Roche Infectious Diseases Molecular Diagnostics Kit Revenue by Application in 2024
11.1.7 Roche Infectious Diseases Molecular Diagnostics Kit Revenue by Geographic Area in 2024
11.1.8 Roche Infectious Diseases Molecular Diagnostics Kit SWOT Analysis
11.1.9 Roche Recent Developments
11.2 Qiagen
11.2.1 Qiagen Corporation Information
11.2.2 Qiagen Business Overview
11.2.3 Qiagen Infectious Diseases Molecular Diagnostics Kit Product Features and Attributes
11.2.4 Qiagen Infectious Diseases Molecular Diagnostics Kit Revenue and Gross Margin (2020-2025)
11.2.5 Qiagen Infectious Diseases Molecular Diagnostics Kit Revenue by Product in 2024
11.2.6 Qiagen Infectious Diseases Molecular Diagnostics Kit Revenue by Application in 2024
11.2.7 Qiagen Infectious Diseases Molecular Diagnostics Kit Revenue by Geographic Area in 2024
11.2.8 Qiagen Infectious Diseases Molecular Diagnostics Kit SWOT Analysis
11.2.9 Qiagen Recent Developments
11.3 Illumina
11.3.1 Illumina Corporation Information
11.3.2 Illumina Business Overview
11.3.3 Illumina Infectious Diseases Molecular Diagnostics Kit Product Features and Attributes
11.3.4 Illumina Infectious Diseases Molecular Diagnostics Kit Revenue and Gross Margin (2020-2025)
11.3.5 Illumina Infectious Diseases Molecular Diagnostics Kit Revenue by Product in 2024
11.3.6 Illumina Infectious Diseases Molecular Diagnostics Kit Revenue by Application in 2024
11.3.7 Illumina Infectious Diseases Molecular Diagnostics Kit Revenue by Geographic Area in 2024
11.3.8 Illumina Infectious Diseases Molecular Diagnostics Kit SWOT Analysis
11.3.9 Illumina Recent Developments
11.4 Abbott
11.4.1 Abbott Corporation Information
11.4.2 Abbott Business Overview
11.4.3 Abbott Infectious Diseases Molecular Diagnostics Kit Product Features and Attributes
11.4.4 Abbott Infectious Diseases Molecular Diagnostics Kit Revenue and Gross Margin (2020-2025)
11.4.5 Abbott Infectious Diseases Molecular Diagnostics Kit Revenue by Product in 2024
11.4.6 Abbott Infectious Diseases Molecular Diagnostics Kit Revenue by Application in 2024
11.4.7 Abbott Infectious Diseases Molecular Diagnostics Kit Revenue by Geographic Area in 2024
11.4.8 Abbott Infectious Diseases Molecular Diagnostics Kit SWOT Analysis
11.4.9 Abbott Recent Developments
11.5 Hologic
11.5.1 Hologic Corporation Information
11.5.2 Hologic Business Overview
11.5.3 Hologic Infectious Diseases Molecular Diagnostics Kit Product Features and Attributes
11.5.4 Hologic Infectious Diseases Molecular Diagnostics Kit Revenue and Gross Margin (2020-2025)
11.5.5 Hologic Infectious Diseases Molecular Diagnostics Kit Revenue by Product in 2024
11.5.6 Hologic Infectious Diseases Molecular Diagnostics Kit Revenue by Application in 2024
11.5.7 Hologic Infectious Diseases Molecular Diagnostics Kit Revenue by Geographic Area in 2024
11.5.8 Hologic Infectious Diseases Molecular Diagnostics Kit SWOT Analysis
11.5.9 Hologic Recent Developments
11.6 BioMerieux
11.6.1 BioMerieux Corporation Information
11.6.2 BioMerieux Business Overview
11.6.3 BioMerieux Infectious Diseases Molecular Diagnostics Kit Product Features and Attributes
11.6.4 BioMerieux Infectious Diseases Molecular Diagnostics Kit Revenue and Gross Margin (2020-2025)
11.6.5 BioMerieux Recent Developments
11.7 Danaher (Cepheid)
11.7.1 Danaher (Cepheid) Corporation Information
11.7.2 Danaher (Cepheid) Business Overview
11.7.3 Danaher (Cepheid) Infectious Diseases Molecular Diagnostics Kit Product Features and Attributes
11.7.4 Danaher (Cepheid) Infectious Diseases Molecular Diagnostics Kit Revenue and Gross Margin (2020-2025)
11.7.5 Danaher (Cepheid) Recent Developments
11.8 Myriad Genetics
11.8.1 Myriad Genetics Corporation Information
11.8.2 Myriad Genetics Business Overview
11.8.3 Myriad Genetics Infectious Diseases Molecular Diagnostics Kit Product Features and Attributes
11.8.4 Myriad Genetics Infectious Diseases Molecular Diagnostics Kit Revenue and Gross Margin (2020-2025)
11.8.5 Myriad Genetics Recent Developments
11.9 DAAN Gene
11.9.1 DAAN Gene Corporation Information
11.9.2 DAAN Gene Business Overview
11.9.3 DAAN Gene Infectious Diseases Molecular Diagnostics Kit Product Features and Attributes
11.9.4 DAAN Gene Infectious Diseases Molecular Diagnostics Kit Revenue and Gross Margin (2020-2025)
11.9.5 DAAN Gene Recent Developments
11.10 Agilent
11.10.1 Agilent Corporation Information
11.10.2 Agilent Business Overview
11.10.3 Agilent Infectious Diseases Molecular Diagnostics Kit Product Features and Attributes
11.10.4 Agilent Infectious Diseases Molecular Diagnostics Kit Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Genomic Health
11.11.1 Genomic Health Corporation Information
11.11.2 Genomic Health Business Overview
11.11.3 Genomic Health Infectious Diseases Molecular Diagnostics Kit Product Features and Attributes
11.11.4 Genomic Health Infectious Diseases Molecular Diagnostics Kit Revenue and Gross Margin (2020-2025)
11.11.5 Genomic Health Recent Developments
11.12 BD
11.12.1 BD Corporation Information
11.12.2 BD Business Overview
11.12.3 BD Infectious Diseases Molecular Diagnostics Kit Product Features and Attributes
11.12.4 BD Infectious Diseases Molecular Diagnostics Kit Revenue and Gross Margin (2020-2025)
11.12.5 BD Recent Developments
11.13 Foundation Medicine
11.13.1 Foundation Medicine Corporation Information
11.13.2 Foundation Medicine Business Overview
11.13.3 Foundation Medicine Infectious Diseases Molecular Diagnostics Kit Product Features and Attributes
11.13.4 Foundation Medicine Infectious Diseases Molecular Diagnostics Kit Revenue and Gross Margin (2020-2025)
11.13.5 Foundation Medicine Recent Developments
12 Infectious Diseases Molecular Diagnostics KitIndustry Chain Analysis
12.1 Infectious Diseases Molecular Diagnostics Kit Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Infectious Diseases Molecular Diagnostics Kit Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Infectious Diseases Molecular Diagnostics Kit Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
TABLE OF FIGURES
List of Tables
Table 1. Global Infectious Diseases Molecular Diagnostics Kit Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Infectious Diseases Molecular Diagnostics Kit Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Infectious Diseases Molecular Diagnostics Kit Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Infectious Diseases Molecular Diagnostics Kit Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Infectious Diseases Molecular Diagnostics Kit Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Infectious Diseases Molecular Diagnostics Kit Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Infectious Diseases Molecular Diagnostics Kit Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Infectious Diseases Molecular Diagnostics Kit by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Infectious Diseases Molecular Diagnostics Kit as of 2024)
Table 11. Global Infectious Diseases Molecular Diagnostics Kit Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Infectious Diseases Molecular Diagnostics Kit Companies Headquarters
Table 13. Global Infectious Diseases Molecular Diagnostics Kit Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Infectious Diseases Molecular Diagnostics Kit Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Infectious Diseases Molecular Diagnostics Kit Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Infectious Diseases Molecular Diagnostics Kit Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Infectious Diseases Molecular Diagnostics Kit Revenue by Application (2026-2031) & (US$ Million)
Table 21. Infectious Diseases Molecular Diagnostics Kit High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Infectious Diseases Molecular Diagnostics Kit Growth Accelerators and Market Barriers
Table 25. North America Infectious Diseases Molecular Diagnostics Kit Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Infectious Diseases Molecular Diagnostics Kit Growth Accelerators and Market Barriers
Table 27. Europe Infectious Diseases Molecular Diagnostics Kit Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Infectious Diseases Molecular Diagnostics Kit Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Infectious Diseases Molecular Diagnostics Kit Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Infectious Diseases Molecular Diagnostics Kit Investment Opportunities and Key Challenges
Table 31. Central and South America Infectious Diseases Molecular Diagnostics Kit Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Infectious Diseases Molecular Diagnostics Kit Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Infectious Diseases Molecular Diagnostics Kit Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Roche Corporation Information
Table 35. Roche Description and Major Businesses
Table 36. Roche Product Features and Attributes
Table 37. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Roche Revenue Proportion by Product in 2024
Table 39. Roche Revenue Proportion by Application in 2024
Table 40. Roche Revenue Proportion by Geographic Area in 2024
Table 41. Roche Infectious Diseases Molecular Diagnostics Kit SWOT Analysis
Table 42. Roche Recent Developments
Table 43. Qiagen Corporation Information
Table 44. Qiagen Description and Major Businesses
Table 45. Qiagen Product Features and Attributes
Table 46. Qiagen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Qiagen Revenue Proportion by Product in 2024
Table 48. Qiagen Revenue Proportion by Application in 2024
Table 49. Qiagen Revenue Proportion by Geographic Area in 2024
Table 50. Qiagen Infectious Diseases Molecular Diagnostics Kit SWOT Analysis
Table 51. Qiagen Recent Developments
Table 52. Illumina Corporation Information
Table 53. Illumina Description and Major Businesses
Table 54. Illumina Product Features and Attributes
Table 55. Illumina Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Illumina Revenue Proportion by Product in 2024
Table 57. Illumina Revenue Proportion by Application in 2024
Table 58. Illumina Revenue Proportion by Geographic Area in 2024
Table 59. Illumina Infectious Diseases Molecular Diagnostics Kit SWOT Analysis
Table 60. Illumina Recent Developments
Table 61. Abbott Corporation Information
Table 62. Abbott Description and Major Businesses
Table 63. Abbott Product Features and Attributes
Table 64. Abbott Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Abbott Revenue Proportion by Product in 2024
Table 66. Abbott Revenue Proportion by Application in 2024
Table 67. Abbott Revenue Proportion by Geographic Area in 2024
Table 68. Abbott Infectious Diseases Molecular Diagnostics Kit SWOT Analysis
Table 69. Abbott Recent Developments
Table 70. Hologic Corporation Information
Table 71. Hologic Description and Major Businesses
Table 72. Hologic Product Features and Attributes
Table 73. Hologic Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Hologic Revenue Proportion by Product in 2024
Table 75. Hologic Revenue Proportion by Application in 2024
Table 76. Hologic Revenue Proportion by Geographic Area in 2024
Table 77. Hologic Infectious Diseases Molecular Diagnostics Kit SWOT Analysis
Table 78. Hologic Recent Developments
Table 79. BioMerieux Corporation Information
Table 80. BioMerieux Description and Major Businesses
Table 81. BioMerieux Product Features and Attributes
Table 82. BioMerieux Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. BioMerieux Recent Developments
Table 84. Danaher (Cepheid) Corporation Information
Table 85. Danaher (Cepheid) Description and Major Businesses
Table 86. Danaher (Cepheid) Product Features and Attributes
Table 87. Danaher (Cepheid) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Danaher (Cepheid) Recent Developments
Table 89. Myriad Genetics Corporation Information
Table 90. Myriad Genetics Description and Major Businesses
Table 91. Myriad Genetics Product Features and Attributes
Table 92. Myriad Genetics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Myriad Genetics Recent Developments
Table 94. DAAN Gene Corporation Information
Table 95. DAAN Gene Description and Major Businesses
Table 96. DAAN Gene Product Features and Attributes
Table 97. DAAN Gene Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. DAAN Gene Recent Developments
Table 99. Agilent Corporation Information
Table 100. Agilent Description and Major Businesses
Table 101. Agilent Product Features and Attributes
Table 102. Agilent Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Agilent Recent Developments
Table 104. Genomic Health Corporation Information
Table 105. Genomic Health Description and Major Businesses
Table 106. Genomic Health Product Features and Attributes
Table 107. Genomic Health Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Genomic Health Recent Developments
Table 109. BD Corporation Information
Table 110. BD Description and Major Businesses
Table 111. BD Product Features and Attributes
Table 112. BD Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. BD Recent Developments
Table 114. Foundation Medicine Corporation Information
Table 115. Foundation Medicine Description and Major Businesses
Table 116. Foundation Medicine Product Features and Attributes
Table 117. Foundation Medicine Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Foundation Medicine Recent Developments
Table 119. Raw Materials Key Suppliers
Table 120. Distributors List
Table 121. Market Trends and Market Evolution
Table 122. Market Drivers and Opportunities
Table 123. Market Challenges, Risks, and Restraints
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Infectious Diseases Molecular Diagnostics Kit Product Picture
Figure 2. Global Infectious Diseases Molecular Diagnostics Kit Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Polymerase Chain Reaction PCR Product Picture
Figure 4. Molecular Hybridization Product Picture
Figure 5. Biochip Product Picture
Figure 6. Others Product Picture
Figure 7. Global Infectious Diseases Molecular Diagnostics Kit Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Hospital
Figure 9. Third-party Testing Agency
Figure 10. Others
Figure 11. Infectious Diseases Molecular Diagnostics Kit Report Years Considered
Figure 12. Global Infectious Diseases Molecular Diagnostics Kit Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2031) & (US$ Million)
Figure 14. Global Infectious Diseases Molecular Diagnostics Kit Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Infectious Diseases Molecular Diagnostics Kit Revenue Market Share by Region (2020-2031)
Figure 16. Global Infectious Diseases Molecular Diagnostics Kit Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. Polymerase Chain Reaction PCR Revenue Market Share by Player in 2024
Figure 19. Molecular Hybridization Revenue Market Share by Player in 2024
Figure 20. Biochip Revenue Market Share by Player in 2024
Figure 21. Others Revenue Market Share by Player in 2024
Figure 22. Global Infectious Diseases Molecular Diagnostics Kit Revenue Market Share by Type (2020-2031)
Figure 23. Global Infectious Diseases Molecular Diagnostics Kit Revenue Market Share by Application (2020-2031)
Figure 24. North America Infectious Diseases Molecular Diagnostics Kit Revenue YoY (2020-2031) & (US$ Million)
Figure 25. North America Top 5 Players Infectious Diseases Molecular Diagnostics Kit Revenue (US$ Million) in 2024
Figure 26. North America Infectious Diseases Molecular Diagnostics Kit Revenue (US$ Million) by Type (2020 - 2031)
Figure 27. North America Infectious Diseases Molecular Diagnostics Kit Revenue (US$ Million) by Application (2020-2031)
Figure 28. US Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2031) & (US$ Million)
Figure 29. Canada Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2031) & (US$ Million)
Figure 30. Mexico Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2031) & (US$ Million)
Figure 31. Europe Infectious Diseases Molecular Diagnostics Kit Revenue YoY (2020-2031) & (US$ Million)
Figure 32. Europe Top 5 Players Infectious Diseases Molecular Diagnostics Kit Revenue (US$ Million) in 2024
Figure 33. Europe Infectious Diseases Molecular Diagnostics Kit Revenue (US$ Million) by Type (2020-2031)
Figure 34. Europe Infectious Diseases Molecular Diagnostics Kit Revenue (US$ Million) by Application (2020-2031)
Figure 35. Germany Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2031) & (US$ Million)
Figure 36. France Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2031) & (US$ Million)
Figure 37. U.K. Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2031) & (US$ Million)
Figure 38. Italy Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2031) & (US$ Million)
Figure 39. Russia Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Infectious Diseases Molecular Diagnostics Kit Revenue YoY (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Top 8 Players Infectious Diseases Molecular Diagnostics Kit Revenue (US$ Million) in 2024
Figure 42. Asia-Pacific Infectious Diseases Molecular Diagnostics Kit Revenue (US$ Million) by Type (2020-2031)
Figure 43. Asia-Pacific Infectious Diseases Molecular Diagnostics Kit Revenue (US$ Million) by Application (2020-2031)
Figure 44. Indonesia Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2031) & (US$ Million)
Figure 45. Japan Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2031) & (US$ Million)
Figure 46. South Korea Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2031) & (US$ Million)
Figure 47. Australia Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2031) & (US$ Million)
Figure 48. India Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2031) & (US$ Million)
Figure 49. Indonesia Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2031) & (US$ Million)
Figure 50. Vietnam Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2031) & (US$ Million)
Figure 51. Malaysia Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2031) & (US$ Million)
Figure 52. Philippines Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2031) & (US$ Million)
Figure 53. Singapore Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2031) & (US$ Million)
Figure 54. Central and South America Infectious Diseases Molecular Diagnostics Kit Revenue YoY (2020-2031) & (US$ Million)
Figure 55. Central and South America Top 5 Players Infectious Diseases Molecular Diagnostics Kit Revenue (US$ Million) in 2024
Figure 56. Central and South America Infectious Diseases Molecular Diagnostics Kit Revenue (US$ Million) by Type (2020-2031)
Figure 57. Central and South America Infectious Diseases Molecular Diagnostics Kit Revenue (US$ Million) by Application (2020-2031)
Figure 58. Brazil Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2025) & (US$ Million)
Figure 59. Argentina Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2025) & (US$ Million)
Figure 60. Middle East and Africa Infectious Diseases Molecular Diagnostics Kit Revenue YoY (2020-2031) & (US$ Million)
Figure 61. Middle East and Africa Top 5 Players Infectious Diseases Molecular Diagnostics Kit Revenue (US$ Million) in 2024
Figure 62. South America Infectious Diseases Molecular Diagnostics Kit Revenue (US$ Million) by Type (2020-2031)
Figure 63. Middle East and Africa Infectious Diseases Molecular Diagnostics Kit Revenue (US$ Million) by Application (2020-2031)
Figure 64. GCC Countries Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2025) & (US$ Million)
Figure 65. Israel Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2025) & (US$ Million)
Figure 66. Egypt Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2025) & (US$ Million)
Figure 67. South Africa Infectious Diseases Molecular Diagnostics Kit Revenue (2020-2025) & (US$ Million)
Figure 68. Infectious Diseases Molecular Diagnostics Kit Industry Chain Mapping
Figure 69. Channels of Distribution (Direct Vs Distribution)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which region is expected to have the highest market share?
For each regional market, the report conducted in-depth comparative analysis from multiple dimensions such as market size, 7.5% compound annual growth rate, market demand, industrial structure, policy environment, and the layout of major enterprises. It systematically summarized the market characteristics and competitive environment of different regions. At the same time, it also focused on analyzing the demand structure, market growth drivers, and investment environment of each region, providing valuable references for enterprises to identify key regional markets, formulate global market layouts and sales strategies.
What is the annual compound growth rate of the global Infectious Diseases Molecular Diagnostics Kit market size from 2025 to 2031?
What was the global market size of Infectious Diseases Molecular Diagnostics Kit in 2025?
What was the global market size of Infectious Diseases Molecular Diagnostics Kit in 2031?
Which companies rank high in the global Infectious Diseases Molecular Diagnostics Kit market?
Related Reports
Infectious Diseases Molecular Diagnostics Kit - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Infectious Diseases Molecular Diagnostics Kit was estimated to be worth US$ 21280 million in 2025 and is projected to reach US$ 35060 million, growing at a CAGR of 7.5% from 2026 to 2032.
Published Date: 2026-06-16
Pages: 115
USD 3950.00
(Single User License)
Global Infectious Diseases Molecular Diagnostics Kit Market Research Report 2026
The global Infectious Diseases Molecular Diagnostics Kit market was valued at US$ 21280 million in 2025 and is anticipated to reach US$ 35060 million by 2032, at a CAGR of 7.5% from 2026 to 2032.
Published Date: 2026-04-17
Pages: 118
USD 2900.00
(Single User License)
Global Infectious Diseases Molecular Diagnostics Kit Market Research Report 2025
The global market for Infectious Diseases Molecular Diagnostics Kit was valued at US$ 19930 million in the year 2024 and is projected to reach a revised size of US$ 32840 million by 2031, growing at a CAGR of 7.5% during the forecast period.
Published Date: 2025-01-16
Pages: 82
USD 2900.00
(Single User License)
Infectious Diseases Molecular Diagnostics Kit- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Infectious Diseases Molecular Diagnostics Kit was estimated to be worth US$ 19930 million in 2024 and is forecast to a readjusted size of US$ 32840 million by 2031 with a CAGR of 7.5% during the forecast period 2025-2031.
Published Date: 2025-01-13
Pages: 108
USD 3950.00
(Single User License)
Global Infectious Diseases Molecular Diagnostics Kit Market Insights, Forecast to 2030
The implications of current trends in molecular infectious diseases are moving towards high-throughput, simple, array-type technologies that will provide a wealth of data regarding types of organisms present in a sample and the virulence factors/resistance determinants that influence the severity of disease. As a result of these developments, infectious diseases will be more accurately and effectively treated.
Published Date: 2024-04-12
Pages: 110
USD 4900.00
(Single User License)
Global Infectious Diseases Molecular Diagnostics Kit Market Research Report 2024
The implications of current trends in molecular infectious diseases are moving towards high-throughput, simple, array-type technologies that will provide a wealth of data regarding types of organisms present in a sample and the virulence factors/resistance determinants that influence the severity of disease. As a result of these developments, infectious diseases will be more accurately and effectively treated.
Published Date: 2024-01-12
Pages: 86
USD 2900.00
(Single User License)
Infectious Diseases Molecular Diagnostics Kit - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The implications of current trends in molecular infectious diseases are moving towards high-throughput, simple, array-type technologies that will provide a wealth of data regarding types of organisms present in a sample and the virulence factors/resistance determinants that influence the severity of disease. As a result of these developments, infectious diseases will be more accurately and effectively treated.
Published Date: 2024-01-08
Pages: 108
USD 3950.00
(Single User License)
Infectious Diseases Molecular Diagnostics Kit - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Infectious Diseases Molecular Diagnostics Kit was estimated to be worth US$ 21280 million in 2025 and is projected to reach US$ 35060 million, growing at a CAGR of 7.5% from 2026 to 2032.
Published: 2026-06-16
Pages: 115
USD 3950.00 (Single User License)Global Infectious Diseases Molecular Diagnostics Kit Market Research Report 2026
The global Infectious Diseases Molecular Diagnostics Kit market was valued at US$ 21280 million in 2025 and is anticipated to reach US$ 35060 million by 2032, at a CAGR of 7.5% from 2026 to 2032.
Published: 2026-04-17
Pages: 118
USD 2900.00 (Single User License)Global Infectious Diseases Molecular Diagnostics Kit Market Research Report 2025
The global market for Infectious Diseases Molecular Diagnostics Kit was valued at US$ 19930 million in the year 2024 and is projected to reach a revised size of US$ 32840 million by 2031, growing at a CAGR of 7.5% during the forecast period.
Published: 2025-01-16
Pages: 82
USD 2900.00 (Single User License)Infectious Diseases Molecular Diagnostics Kit- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Infectious Diseases Molecular Diagnostics Kit was estimated to be worth US$ 19930 million in 2024 and is forecast to a readjusted size of US$ 32840 million by 2031 with a CAGR of 7.5% during the forecast period 2025-2031.
Published: 2025-01-13
Pages: 108
USD 3950.00 (Single User License)Global Infectious Diseases Molecular Diagnostics Kit Market Insights, Forecast to 2030
The implications of current trends in molecular infectious diseases are moving towards high-throughput, simple, array-type technologies that will provide a wealth of data regarding types of organisms present in a sample and the virulence factors/resistance determinants that influence the severity of disease. As a result of these developments, infectious diseases will be more accurately and effectively treated.
Published: 2024-04-12
Pages: 110
USD 4900.00 (Single User License)Global Infectious Diseases Molecular Diagnostics Kit Market Research Report 2024
The implications of current trends in molecular infectious diseases are moving towards high-throughput, simple, array-type technologies that will provide a wealth of data regarding types of organisms present in a sample and the virulence factors/resistance determinants that influence the severity of disease. As a result of these developments, infectious diseases will be more accurately and effectively treated.
Published: 2024-01-12
Pages: 86
USD 2900.00 (Single User License)Infectious Diseases Molecular Diagnostics Kit - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The implications of current trends in molecular infectious diseases are moving towards high-throughput, simple, array-type technologies that will provide a wealth of data regarding types of organisms present in a sample and the virulence factors/resistance determinants that influence the severity of disease. As a result of these developments, infectious diseases will be more accurately and effectively treated.
Published: 2024-01-08
Pages: 108
USD 3950.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now